A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer Meeting Abstract
| Authors: | Girda, E.; Makker, V.; Marth, C.; Van Gorp, T.; Mirza, M.; Shapira-Frommer, R.; Suttner, L.; Groisberg, R.; Jin, F.; O'Malley, D. |
| Abstract Title: | A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S293 |
| End Page: | S294 |
| Language: | English |
| ACCESSION: | WOS:001330731400426 |
| DOI: | 10.1016/j.ygyno.2024.07.438 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2140 [TIP] -- Source: Wos |
